Study reveals that stool samples can diagnose Autism

Researchers have discovered disparities in the intestinal microbiomes of autistic individuals, which raises expectations for a more rapid diagnosis.

• 

Imaging the human gut microbiome under an electron microscope. Photo Reproduction/nopparit/Getty Images

A recently published groundbreaking study brought a surprising discovery in the field of health: Stool samples can be used to diagnose Autism Spectrum Disorder (TEA). Professor Qi Su from the Chinese University of Hong Kong, together with his colleagues, led a study to deepen understanding of the link between the gut microbiome and neurological development.

This research brings a new perspective on the diagnosis of autism, using an accessible and simple test that identifies consistent differences in gut microbes of autistic individuals compared to individuals without the condition. This finding suggests that a routine stool test could help doctors detect autism early. This could mean quicker diagnoses and support for people, in contrast to the lengthy procedures currently employed in clinics.

According to Su, it generally takes three to four years to confirm the diagnosis of autism after initial suspicions, with most children receiving the diagnosis around six years of age. The use of the microbiome biomarker panel shows promising results in children under four years of age, which can significantly contribute to early diagnosis.

Study Methodology

Twin studies indicate that between 60% and 90% of autism cases have a genetic basis, but there are other factors at play, such as the advanced age of the parents, birth complications, and exposure during pregnancy to air pollution or certain pesticides. The signs of Autism can range from children who do not respond to their name and avoid eye contact to adults who face difficulties understanding thoughts of neurotypical people and suffer from anxiety when their routine is changed.

Scientists have long observed that autistic people tend to have a reduced diversity of bacteria in their gut, but whether this is a consequence of autism or somehow contributes to the condition is still a matter of debate. To delve deeper into the puzzle, Su and his colleagues examined stool samples from 1,627 children aged between one and 13 years, including some who were autistic. They analyzed the samples for the presence of various bacteria, viruses, fungi and other microbes known as archaea.

In a paper published in Nature Microbiology, researchers described significant differences in the composition of gut microbes between children with autism and those without the condition. They identified that a total of 51 types of bacteria, 18 viruses, 14 archaea, seven fungi and several metabolic pathways were altered in autistic children.

Promising Results

The results of the study are promising and indicate that it is possible to identify ASD with considerable accuracy just by analyzing stool samples. Using machine learning, a form of artificial intelligence, scientists were able to distinguish children with autism with an accuracy of up to 82%, based on analysis of 31 microbes and biological functions in the digestive system. The study also identified other changes, indicating that several metabolic pathways related to energy and neurodevelopment appear to be compromised in autistic children.

“Although genetic factors perform a substantial role in autism, the microbiome may act as a contributing factor by modulating immune responses, neurotransmitter production and metabolic pathways,” said Su. “This does not necessarily imply causality, but it does suggest that the microbiome may influence the severity or expression of autism spectrum symptoms.”

Future Implications

This approach can complement current diagnostic methods, which rely primarily on behavioral and psychological assessments. The researchers suggest that if altering the microbiome is confirmed to influence the severity of autism, this could pave the way for personalized interventions. These could include specific diets or the use of probiotics to promote a more diverse microbiome in individuals diagnosed with this condition.

This perspective expands the possibilities to develop more effective and less invasive diagnostic tools and therapeutic strategies for autism. According to Su, "We are currently conducting a clinical trial to investigate whether analysis of fecal samples can help identify signs of autism in children as young as twelve months of age."

Dr. Dominic Farsi, from King's College London, considered that the results have "significant potential" in diagnostic practice. However, he emphasized that more research is needed to validate these findings. "Nevertheless, these findings may represent a significant advance in improving diagnostic methods for autism spectrum disorder," he said.

Dr. Elizabeth Lund, an independent nutrition and gastrointestinal health consultant, expressed optimism about the potential of stool sample analysis in diagnosis. She highlighted the urgency of a more streamlined alternative to the currently lengthy process that many children and adults face while waiting for assessments. Dr. Lund noted that there is a shortage of trained professionals, such as psychologists and psychiatrists, capable of providing adequate diagnoses. She highlighted the need for replication of the study by different groups around the world to validate the approach, but envisions the possibility of a new, automated route for long-term diagnosis.